Ivabradine Hydrochloride

• CAT Number: I007403
• CAS Number: 148849-67-6
• Molecular Formula: C₂₇H₃₆N₂O₅·HCl
• Molecular Weight: 505.10
• Purity: ≥95%
• Synonyms: S16257; S 16257; S-16257; Ivabradine HCl; Brand name: Corlentor (US); Procoralan (worldwide); Coralan; Coraxan; Ivabid; Bradia.;(S)-3-(3-(((3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl)methyl)(methyl)amino)propyl)-7,8-dimethoxy-1,3,4,5-tetrahydro
• Target: HCN Channel
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4°C for short term , or -20°C for long term.
• InChI: InChI=1S/C27H36N2O5.ClH/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30;/h12-14,16,21H,6-11,15,17H2,1-5H3;1H/t21-;/m1./s1
• InChIKey: HLUKNZUABFFNQS-ZMBIFBSDSA-N
• SMILES: CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)CC3CC4=CC(=C(C=C34)OC)OC.Cl

Ivabradine hydrochloride (Cat No.: I007403) is a heart rate-reducing agent that selectively inhibits the If current (funny current) in the sinoatrial node, without affecting myocardial contractility or blood pressure. It is primarily used to treat chronic stable angina and heart failure with reduced ejection fraction (HFrEF) in patients intolerant to or inadequately managed by beta-blockers. By lowering heart rate, Ivabradine improves myocardial oxygen supply and reduces cardiac workload. Its unique mechanism makes it valuable in cardiovascular research and in managing patients with elevated resting heart rates.

Reference

1:J Mass Spectrom. 2015 Feb;50(2):344-53. doi: 10.1002/jms.3533. Characterization of degradation products of ivabradine by LC-HR-MS/MS: a typical case of exhibition of different degradation behaviour in HCl and H2SO4 acid hydrolysis.Patel PN,Borkar RM,Kalariya PD,Gangwal RP,Sangamwar AT,Samanthula G,Ragampeta S, PMID: 25800016 DOI: 10.1002/jms.3533
Abstract: A validated stability-indicating HPLC method was established, and comprehensive stress testing of ivabradine, a cardiotonic drug, was carried out as per ICH guidelines. Ivabradine was subjected to acidic, basic and neutral hydrolysis, oxidation, photolysis and thermal stress conditions, and the resulting degradation products were investigated by LC-PDA and LC-HR-MS/MS. The drug was found to degrade in acid and base hydrolysis. An efficient and selective stability assay method was developed on Phenomenex Luna C18 (250 × 4.6 mm, 5.0 μm) column using ammonium formate (10 mM, pH 3.0) and acetonitrile as mobile phase at 30 °C in gradient elution mode. The flow rate was 0.7 ml/min and detection wavelength was 286 nm. A total of five degradation products (I-1 to I-5) were identified and characterized by LC-HR-MS/MS in combination with accurate mass measurements. The drug exhibited different degradation behaviour in HCl and H2SO4 hydrolysis conditions. It is a unique example where two of the five degradation products in HCl hydrolysis were absent in H2SO4 acid hydrolysis. The present study provides guidance to revise the stress test for the determination of inherent stability of drugs containing lactam moiety under hydrolytic conditions. Most probable mechanisms for the formation of degradation products have been proposed on the basis of a comparison of the fragmentation pattern of the drug and its degradation products. In silico toxicity revealed that the degradation products (I-2 to I-5) were found to be severe irritants in case of ocular irritancy. The analytical assay method was validated with respect to specificity, linearity, range, precision, accuracy and robustness.Copyright © 2015 John Wiley & Sons, Ltd.